In mice, taking phytic acid orally at a dose of 2% of body weight increases HDAC3 enzyme activity, decreases a specific chemical modification on histones near genes that break down tissue, lowers the...

In mice with inflammatory bowel disease or IPMK deficiency, consuming phytic acid at a dose of 2% of body weight increases HDAC3 activity, lowers acetylation at specific gene regions, reduces levels of MMP proteins, and improves intestinal barrier function.

In mice with a specific genetic modification affecting gut cells, consuming phytic acid at a dose of 2% of body weight restores HDAC3 enzyme function, decreases a specific epigenetic mark on genes that produce matrix metalloproteinases, lowers the production of these enzymes, and improves the integrity of the intestinal barrier.

In mice, taking phytic acid orally reduces colon inflammation caused by a chemical irritant by regulating specific enzymes and maintaining the integrity of the intestinal lining, even when another related enzyme is not present.

When the IPMK gene is disabled in gut lining cells of mice, it leads to lower levels of a specific molecule (InsP6), reduced activity of an enzyme (HDAC3), and changes in gene regulation that increase the production of enzymes that break down structural barriers. This results in a leakier intestinal barrier.

In mouse intestinal cells, removing the IPMK gene lowers a specific molecule called InsP6, which interferes with a protein complex that controls gene activity. This causes changes in gene expression that lead to the breakdown of proteins holding intestinal cells together, resulting in increased leakage through the intestinal barrier.